EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY-NC 3.0

Indication Expansion Dynamics and Trial Characteristics of Novel Multi-Indication Anti-Cancer Drugs in China (2000–2024): A Cross-Sectional Study

Xiaoyi Chen iD, Huan Li iD, Shunlong Ou iD, Zhisan He iD, Dongni Zheng iD, Jing Luo iD, Qian Jiang iD

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s551402 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Xiaoyi Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsCross-Sectional StudiesHumansChinaDrug ApprovalClinical Trials as Topic

Stichwörter der Autor:innen

NMPA approvalindication expansionmulti-indicationpivotal trialtargeted therapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Peo…
  • Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, People's Republic of Ch…
  • Department of Pharmacy, The Fifth People's Hospital of Chengdu, Chengdu, Sichuan, People's Republic of China.
  • Department of Pharmacy, The Second People's Hospital of Yibin, Yibin, Sichuan, People's Republic of China.

ORCID-Profile: Xiaoyi Chen, Huan Li, Shunlong Ou, Zhisan He, Dongni Zheng, Jing Luo, Qian Jiang

Zitieren

APA

Chen, X., Li, H., Ou, S., He, Z., Zheng, D., Luo, J., & Jiang, Q. (2026). Indication Expansion Dynamics and Trial Characteristics of Novel Multi-Indication Anti-Cancer Drugs in China (2000–2024): A Cross-Sectional Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s551402

Vancouver

Chen X, Li H, Ou S, He Z, Zheng D, Luo J, et al. Indication Expansion Dynamics and Trial Characteristics of Novel Multi-Indication Anti-Cancer Drugs in China (2000–2024): A Cross-Sectional Study. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s551402

BibTeX
@article{Chen2026,
  author = {Chen, Xiaoyi and Li, Huan and Ou, Shunlong and He, Zhisan and Zheng, Dongni and Luo, Jing and Jiang, Qian},
  title = {Indication Expansion Dynamics and Trial Characteristics of Novel Multi-Indication Anti-Cancer Drugs in China (2000–2024): A Cross-Sectional Study},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s551402}
}
Kostenlos starten →